fudan university shanghai cancer center breast cancer precision platform series study- neoadjuvant therapy

Conditions: Breast Neoplasm; Breast Cancer; Breast Tumors; Triple-Negative Breast Cancer (TNBC); HER2-positive Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Hormone Receptor Negative Tumor; Early-stage Breast Cancer; Locally Advanced Breast Cancer

Summary: the purpose of this study is to establish a prospective, single-center platform research based on clinical subtypes to explore precision neoadjuvant therapy in patients with operable breast cancer who met the indications for neoadjuvant chemotherapy and by the update of basic translational research in the center, especially the refinement of typing, the discovery of new targets and the development of novel targeted drugs, verified the effectiveness of new targeted drugs in neoadjuvant therapy.

fascinate-n is a platform that will compare the efficacy of novel drugs alone or in combination with standard chemotherapy with the efficacy of standard therapy alone. the goal is to identify improved treatment regimens for subsets on the basis of clinical subtyping. in this trial, breast cancer patients eligible for inclusion can be randomly divided into the precision treatment group and conventional neoadjuvant chemotherapy group according to molecular typing and subtyping. the research therapy arm can be updated with the update of basic translational research in our center, especially the refinement of typing, the discovery of new targets and the development of novel targeted drugs. as described for previous adaptive trials, regimens that show to be more effective than standard therapy will graduate from the trial with their corresponding biomarker signature(s). regimens will be dropped if they show a low probability of improved efficacy with any biomarker signature. new drugs will enter as those that have undergone testing complete their evaluation.

Eligibility criteria:
inclusion criteria: * histologically confirmed invasive cancer of the breast and meet the clinical stage ii（t2n0-1m0/t3n0m0）or iii（t2n2m0/t3n1-2m0) criteria; * age between18-70 years; * eastern cooperative oncology group (ecog) performance status 0-1; * er, pr and her2 status were measured by immunohistochemistry (ihc); * lvef≥55%； * definition of snf subtypes: snf subtypes confirmed by digital pathology of h\&e slices; * triple negative subtyping: on the basis of triple-negative pathological diagnosis, ar, cluster of differentiation 8 (cd8) and forkhead box c1 (foxc1) were combined to define the subtyping; * at least one measurable lesion according to recist version 1.1 * normal organ and marrow function: hemoglobin (hb) ≥90 g/l (no blood was transfused within 14 days), absolute neutrophil count ≥ 1500/μl, platelets ≥ 75,000/μl, total bilirubin ≤ 1.5 x uln), aspartate aminotransferase (ast) (sgot) and alanine aminotransferase (alt) (sgpt) ≤ 3 x uln, creatinine \ 50 ml/min (cockcroft-gault formula); * non-pregnant and non-lactating, fertile female subjects were required to use a medically approved contraceptive method for the duration of the study treatment and at least 3 months after the last use of the study drug; * ability to understand and willingness to sign a written informed consent exclusion criteria: * previous cytotoxic chemotherapy, endocrine therapy, biological therapy or radiotherapy for any reason; * patients with new york heart association (nyha) grade ii or above heart disease (including grade ii); * patients with severe systemic infections or other serious diseases; * patients with known allergy or intolerance to the study drug or its excipients; * other malignant tumors in the past 5 years, except cured cervical carcinoma in situ and non-melanoma skin cancer; * pregnant or lactating patients of childbearing age who refused to take appropriate contraceptive measures during the course of the study; * participated in other trial studies within 30 days before the administration of the first dose of the study drug; * patients who were judged by the investigator to be unsuitable for this study.